This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Prothena Achieves Orphan Drug Status In EU For Lead Program NEOD001

DUBLIN, Ireland, Feb. 27, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that the European Medicines Agency (EMA) granted orphan designation for its lead program, NEOD001, for the potential treatment of amyloid light-chain (AL) amyloidosis. In 2012, the US Food and Drug Administration (FDA) granted orphan drug status to this program. NEOD001 is a monoclonal antibody that specifically targets the amyloid that accumulates in the organs of patients with the disease.

"AL amyloidosis is the most common and pathogenic form of systemic amyloidoses, and securing orphan designation for NEOD001 in the European Union is an important milestone for Prothena and for patients," said Dale Schenk, PhD, Prothena's President and Chief Executive Officer. "NEOD001 targets systemic amyloidoses, diseases in which misfolded proteins accumulate in the body's organs, causing progressive damage and death. We expect to start Phase I clinical trials of NEOD001 in primary amyloidosis patients early this year. If proven effective in clinical trials, our approach has the potential to provide a novel therapy for this orphan disease with significant unmet medical need." 

"Orphan drug designations support our global development strategy for NEOD001 and our goal of providing improved therapies for patients with amyloidoses," said Gene Kinney, PhD, Prothena's Chief Scientific Officer and Head of Research and Development. "Our preclinical experience to date with NEOD001 has indicated its potential in this disease area, where limited treatment options exist. The orphan drug designations in the EU and the US provide recognition of the need for therapeutics in this area and help advance the development of potential treatments for patients."

About NEOD001

NEOD001 is a monoclonal antibody that specifically targets the amyloid that accumulates in both AL and secondary systemic amyloidosis. If proven safe and effective in clinical trials, this approach has the potential to be a first-in-class agent for this orphan disease with a significant unmet medical need. In 2012, NEOD001 was granted orphan drug designation by the FDA, and an Investigational New Drug application for NEOD001 in systemic amyloidosis was filed. Prothena plans to initiate a Phase 1 clinical trial for NEOD001 in this indication in early 2013. NEOD001 is being developed by Onclave Therapeutics, Limited, a wholly-owned subsidiary of Prothena. More information on the planned clinical trial for NEOD001 is available on

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs